Viabahn覆膜支架与Supera编织型镍钛合金支架治疗严重钙化股腘动脉病变的回顾性多中心比较:ARMADILLO研究(钙化病变中支架的校正回顾性比较)
该回顾性多中心研究比较了覆膜支架(CSG)与Supera编织型镍钛合金支架(SPS)治疗双侧钙化股腘动脉病变的安全性和有效性。倾向性评分匹配后150例患者中,两组1年一期通畅率(81.4% vs 71.2%,p=0.32)、免于靶病变血运重建率(82.8% vs 77.6%,p=0.28)和总生存率(88.6% vs 87.2%,p=0.81)均无统计学显著差异。
要点
- 倾向性评分匹配后,CSG组与SPS组1年一期通畅率无统计学显著差异(81.4% vs 71.2%,p=0.32)。
- 两组免于靶病变血运重建率(82.8% vs 77.6%,p=0.28)和总生存率(88.6% vs 87.2%,p=0.81)均无显著差异。
- 高龄、当前吸烟、糖尿病和PACSS 4级对CSG与SPS植入和再狭窄的关联存在显著交互作用(交互p<0.05)。
核心结论
- 在双侧钙化股腘动脉病变患者中,倾向性评分匹配后,CSG与SPS治疗的1年一期通畅率无统计学显著差异。
研究设计与样本
- 回顾性分析2017年4月至2021年2月日本7个心血管中心341例接受CSG(n=137)或SPS(n=204)EVT的Rutherford 2至6级外周动脉疾病患者,病变为透视影像双侧钙化(基于PACSS分类)。
- 倾向性评分匹配后最终研究人群为150例匹配患者,基线特征组间无显著差异。
主要发现
- CSG组与SPS组1年一期通畅率分别为81.4%和71.2%,无统计学显著差异(p=0.32)。
- CSG组与SPS组免于靶病变血运重建率分别为82.8%和77.6%,无显著差异(p=0.28)。
- CSG组与SPS组总生存率分别为88.6%和87.2%,无显著差异(p=0.81)。
- 分层分析显示高龄、当前吸烟、糖尿病和PACSS 4级对CSG与SPS植入和再狭窄的关联存在显著交互作用(交互p<0.05)。
临床怎么用
- 原文结论指出,在双侧钙化股腘动脉病变患者中,倾向性评分匹配后CSG与SPS治疗的1年一期通畅率无显著差异。
- 原文临床影响部分指出,CSG和SPS是钙化股腘动脉病变中可靠的腔内器具,两种器具在钙化股腘动脉病变中显示出相似的有效性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The previous single-arm registries showed the acceptable primary patency after endovascular therapy (EVT) using covered stent-graft (CSG) and Supera interwoven nitinol stent (Supera peripheral stent [SPS]) in calcified femoropopliteal lesions. The aim of this study was to compare the safety and efficacy between CSG and SPS in calcified femoropopliteal lesions in clinical practice. MATERIALS AND METHODS: We retrospectively analyzed 341 cases who had Rutherford class 2 to 6 peripheral artery disease and underwent EVT with either CSG (n=137) or SPS (n=204) for femoropopliteal lesions with bilateral calcification in fluoroscopic image, based on the Peripheral Arterial Calcium Scoring System (PACSS) classification, between April 2017 and February 2021 at 7 cardiovascular centers in Japan. RESULTS: After propensity score (PS) matching, the final study population consisted of 150 matched patients with no remarkable intergroup difference in baseline characteristics. The primary patency at 1 year was not statistically different between CSG and SPS groups (81.4% vs 71.2%, p=0.32). There was also no significant difference in freedom from target lesion revascularization (82.8% vs 77.6%, p=0.28) and overall survival rate (88.6% vs 87.2%, p=0.81). The stratification analysis demonstrated that advanced age, current smoking, diabetes mellitus, and PACSS grade 4 had a significant interaction on the association of CSG versus SPS implantation with restenosis (interaction p<0.05). CONCLUSIONS: In patients with bilaterally calcified femoropopliteal lesions, 1-year primary patency was not significantly different between treatments using CSG and SPS after the PS matching. CLINICAL IMPACT: Covered stent-graft (CSG) and Supera interwoven nitinol stent (SPS) are reliable endovascular devices in calcified femoropopliteal lesions. This retrospective multicenter study compared the clinical outcomes between the two devices. After propensity score matching, 150 matched patients with no remarkable intergroup difference in baseline characteristics. The primary patency at 1 year was not statistically different between the CSG and SPS group (81.4% vs. 71.2%, p=0.32). There was also no significant difference in freedom from target lesion revascularization (82.8% vs. 77.6%, p=0.28) and overall survival rate (88.6% vs 87.2%, p=0.81). The two devices showed the similar efficacy in calcified femoropopliteal lesions.
引用
- Horie K, Takahara M, Nakama T, et al. Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns). J Endovasc Ther. 2022. PMID: 36146948. doi:10.1177/15266028221124727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。